Ophthalmic drug delivery devices and pharmaceutical products
Strategic Profile
The micro-dosing technology has the potential to replace traditional macro-dosing applications (e.g. conventional eye droppers that deliver 30-50 µL) and achieve similar pharmacologic effects while reducing adverse effects. The company is developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications.
Cyborg Score Rationale
Eyenovia has achieved FDA approvals for two products (Mydcombi and Clobetasol) and demonstrated commercialization capability. The proprietary Optejet platform offers significant patent protection through 2041 and enables a licensable, multi-indication strategy. However, as a smaller public company, the company faces execution risk and capital intensity typical of biopharma.
Top Insights
Eyenovia licensed clobetasol propionate ophthalmic suspension 0.05% from Formosa in August 2023, which was approved by the FDA in March 2024 and represents the first new ophthalmic steroid approved in 15 years.
The company entered into a collaboration agreement with Senju Pharmaceutical in July 2024 to develop SJP-0035 for use with Eyenovia's Optejet dispensing technology as a potential treatment for chronic dry eye disease.
Eyenovia has commenced manufacturing registration batches of Mydcombi using the advanced Gen-2 Optejet dispensing platform, designed for an optimized user experience and extended patent protection through 2041.
The company expects to complete testing of Mydcombi registration batches by the end of 2025, with a potential SNDA filing in early 2026.
Named Competitors
Bausch + Lomb ULTRA/PureVision — Leading ophthalmic pharmaceuticals and devices
Restasis/Xiidra — Dry eye and ocular surface disease therapies
Ocular Surface Disease Portfolio — Comprehensive ophthalmic pharmaceutical and surgical care
Optejet Technology — Proprietary micro-dose array print platform for ocular drug delivery
Recent Developments
(May 2026) Clobetasol propionate ophthalmic suspension commercially available in US as first new ophthalmic steroid approved in 15+ years
(March 2025) Commenced manufacturing of Gen-2 Optejet registration batches with anticipated SNDA filing expected in early 2026
(July 2024) Signed collaboration agreement with Senju Pharmaceutical for chronic dry eye disease treatment targeting Phase 3 studies by 2026
Open the full interactive Eyenovia, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.